These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38279515)

  • 21. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
    Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non-small cell lung cancer.
    Huang CY; Huang HL; Lan CC; Huang YC; Wu YK
    BMC Cancer; 2023 May; 23(1):413. PubMed ID: 37158884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
    Ninomiya T; Ishikawa N; Kozuki T; Kuyama S; Inoue K; Yokoyama T; Kanaji N; Yasugi M; Shibayama T; Aoe K; Ochi N; Fujitaka K; Kodani M; Ueda Y; Watanabe K; Bessho A; Sugimoto K; Oze I; Hotta K; Kiura K
    Lung Cancer; 2023 Oct; 184():107349. PubMed ID: 37651927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
    Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
    Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
    Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
    Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    Tan WL; Ng QS; Lim C; Tan EH; Toh CK; Ang MK; Kanesvaran R; Jain A; Tan DSW; Lim DW
    BMC Cancer; 2018 Dec; 18(1):1198. PubMed ID: 30509246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Ichihara E; Kuyama S; Kudo K; Bessho A; Sakugawa M; Fujimoto N; Aoe K; Minami D; Sugimoto K; Ochi N; Takigawa N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Aug; 51(8):1269-1276. PubMed ID: 34115855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP
    BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
    Kim TH; Choi JH; Ahn MS; Lee HW; Kang SY; Choi YW; Koh YW; Sheen SS
    BMC Cancer; 2024 Jan; 24(1):70. PubMed ID: 38216948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
    Gursoy P; Tatli AM; Erdem D; Goker E; Celik E; Demirci NS; Sakin A; Atci MM; Bayram E; Telli TA; Bilgin B; Bilici A; Akangunduz B; Balli S; Demirkazik A; Selçukbiricik F; Menekse S; Cavdar E; Ozturk A; Bekmez ET; Turhal S; Kilickap S; Yildirim HÇ; Oyan B; Aksoy A; Turkoz FP; Kut E; Katgi N; Sakalar T; Akyol M; Ellez Hİ; Topcu A; Erdoğan AP; Pilanci KN; Hedem E; Arak H; Akdeniz N; Alan Ö; Yapar B; Nart D; Yumuk PF
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):865-875. PubMed ID: 35381885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
    Igawa S; Ono T; Kasajima M; Kusuhara S; Otani S; Fukui T; Yokoba M; Kubota M; Katagiri M; Mitsufuji H; Sasaki J; Naoki K
    Invest New Drugs; 2020 Dec; 38(6):1906-1914. PubMed ID: 32415486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.